Augustine Therapeutics

Private

LeuvenHealthcare & Life Scienceshttps://www.augustinetx.com/

Last Round

Series A

Mar 24, 2025

Total Funding Raised

$108.08M

Company Overview

Augustine Therapeutics is a biotechnology company that develops therapeutic drugs designed to treat neuromuscular and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

HDAC6 inhibitorssmall molecule drugsCharcot-Marie-Tooth diseaseCMTneuromuscular disease treatmentselective HDAC6 inhibitorclinical stage biotechrare disease therapeuticsdrug discoveryneurodegenerative disease treatmentperipheral nerve disorderpharma licensingALS treatmentcardiometabolic disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Augustine Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Augustine Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Augustine Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Mar 24, 2025
Series A	Jun 26, 2024
Seed	Feb 26, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Gerhard Koenig

Chief Executive Officer

Executive Team

Augustine Therapeutics Investors

Notable investors and investment history

Augustine Therapeutics investors
Investor	Rounds
Asabys Partners	Series A
Newton Biocapital	Series A
KU Leuven Research & Development (LRD)	Seed, Series A
V-Bio Ventures	Series A, Seed
Novo Holdings	Series A
PMV	Seed, Series A
VIB	Seed, Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 20, 2026
Monthly visitors grew 406% MoM, reaching 3.1K.
Jan 2, 2026
Monthly visitors grew 101% MoM, reaching 1.2K.

View all signals

Augustine Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Augustine Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Augustine Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeuven

Employee Range24

Year Founded2019

Last FundingMar 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.